Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2013IS029 Principal Investigator Greeno, Edward
Phase Phase III (Cancer Control)
Age Group Adult Scope National
Secondary Protocol No. EMR200592-001
Title A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Applicable Disease Sites Pancreas
Drugs Involved GEMCITABINE (GEMZAR)
PLACEBO
TH-302
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Carrie McCann Phone:612-626-2569
Email:mcca0313@umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on